Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA A Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Foucar K, Rydell RE. Richter's syndrome in chronic lymphocytic leukemia. Cancer. 1980;46(1):118–134.
   PubMed Web of Science ®Google Scholar
• Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):240–249.
   PubMed Web of Science ®Google Scholar
• Molica S, Polliack A. Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. Leuk Res. 2016;50:31–36.
   PubMed Web of Science ®Google Scholar
• Greene MH, Hoover RN, Fraumeni JF. Jr. Subsequent cancer in patients with chronic lymphocytic leukemia: a possible immunologic mechanism. J Natl Cancer Inst. 1978;61(2):337–340.
   PubMedGoogle Scholar
• Mellemgaard A, Geisler CH, Storm HH. Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia. Eur J Haematol. 1994;53(4):218–222.
   PubMed Web of Science ®Google Scholar
• Kyasa MJ, Hazlett L, Parrish RS, et al. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma. 2004;45(3):507–513.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009;27(6):904–910.
   PubMed Web of Science ®Google Scholar
• Royle JA, Baade PD, Joske D, et al. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer. 2011;105(7):1076–1081.
   PubMed Web of Science ®Google Scholar
• Kumar V, Ailawadhi S, Bojanini L, et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019;9(10):75.
   PubMedGoogle Scholar
• Zheng G, Chattopadhyay S, Sud A, et al. Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. Br J Haematol. 2019;185(2):232–239.
   PubMed Web of Science ®Google Scholar
• Falchi L, Vitale C, Keating MJ, et al. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Annals of Oncology: official Journal of the European Society for Medical Oncology. 2016;27(6):1100–1106.
   PubMed Web of Science ®Google Scholar
• Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56(6):1643–1650.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999;17(8):2454–2460.
   PubMed Web of Science ®Google Scholar
• Chavez JC, Dalia S, Sandoval-Sus J, et al. Second myeloid malignancies in a large cohort of patients with chronic lymphocytic leukemia: a single institution experience. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S14–S8.
   PubMedGoogle Scholar
• Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178(3):394–402.
   PubMed Web of Science ®Google Scholar
• Brewer JD, Shanafelt TD, Khezri F, et al. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a rochester epidemiology project population-based study in Minnesota. J Am Acad Dermatol. 2015;72(2):302–309.
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Alexandrescu DT. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed. 2007;9(4):35.
   PubMedGoogle Scholar
• Palma M, Gentilcore G, Heimersson K, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102(3):562–572.
   PubMed Web of Science ®Google Scholar
• Garrett GL, Blanc PD, Boscardin J, et al. Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol. 2017;153(3):296–303.
   PubMed Web of Science ®Google Scholar
• Adami J, Gäbel H, Lindelöf B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–1227.
   PubMed Web of Science ®Google Scholar
• Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a Meta-analysis. The Lancet. 2007;370(9581):59–67.
   PubMed Web of Science ®Google Scholar
• Solomon BM, Chaffee KG, Moreira J, et al. Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia. 2016;30(2):331–336.
   PubMed Web of Science ®Google Scholar
• Dong N, Saeed H, Gaballa S, et al. Survival trend of chronic lymphocytic leukemia and prognostic factors in the United States: an analysis of the national cancer database. J Clin Oncol. 2020;38(15_suppl):e20012–e20012.
   Web of Science ®Google Scholar
• van der Straten L, Levin M-D, Visser O, et al. Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016. Br J Haematol. 2020;189(3):574–577.
   PubMed Web of Science ®Google Scholar
• Ishdorj G, Beiggi S, Nugent Z, et al. Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leuk Lymphoma. 2019;60(13):3204–3213.
   PubMed Web of Science ®Google Scholar
• Pleyer C, Wiestner A, Sun C. Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59(12):2792–2799.
   PubMed Web of Science ®Google Scholar
• Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127(8):3052–3064.
   PubMed Web of Science ®Google Scholar
• Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 2020;34(12):3197–3205.
   PubMed Web of Science ®Google Scholar
• Schollkopf C, Rosendahl D, Rostgaard K, et al. Risk of second cancer after chronic lymphocytic leukemia. Int J Cancer. 2007;121(1):151–156.
   PubMed Web of Science ®Google Scholar
• Herr MM, Schonfeld SJ, Dores GM, et al. Mutual risks of cutaneous melanoma and specific lymphoid neoplasms: second cancer occurrence and survival. J Natl Cancer Inst. 2018;110(11):1248–1258.
   PubMedGoogle Scholar
• Tsai H-T, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 2009;114(24):4928–4932.
   PubMed Web of Science ®Google Scholar
• Landgren O, Rapkin JS, Caporaso NE, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood. 2007;109(5):2198–2201.
   PubMed Web of Science ®Google Scholar
• Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T cells in chronic lymphocytic leukemia: a two-edged sword. Front Immunol. 2020;11:612244.
   PubMed Web of Science ®Google Scholar
• Bernues M, Duran MA, Puget G, et al. Genetics of lymphocytes influences the emergence of second cancer in chronic lymphocytic leukemia. Anticancer Res. 2014;34(5):2311–2314.
   PubMed Web of Science ®Google Scholar
• Morton LM, Hartge P, Holford TR, et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the international lymphoma epidemiology consortium (interlymph). Cancer Epidemiol Biomarkers Prev. 2005;14(4):925–933.
   PubMed Web of Science ®Google Scholar